← Eichor
Study identifier: NCT05910827 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Condition: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer · Advanced Head and Neck Squamous Cell Carcinoma · Advanced Esophageal Squamous Cell Carcinoma  ·  Sponsor: Hummingbird Bioscience

PhasePhase 1/Phase 2
Planned participants398
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers

This description comes directly from the study's public registry record.

Talk to the study team

Kevin Heller, Dr  ·  +65 6978 9377  ·  k.heller@hummingbirdbio.com

Always discuss trial participation with your own doctor first.

Locations (20)

GenesisCare North ShoreSydney, New South Wales, AustraliaWithdrawn
Westmead HospitalWestmead, New South Wales, AustraliaRecruiting
ICON Cancer Centre South BrisbaneBrisbane, Queensland, AustraliaWithdrawn
Greenslopes Private HospitalGreenslopes, Queensland, AustraliaRecruiting
Southern Oncology Clinical Research UnitAdelaide, South Australia, AustraliaRecruiting
Peninsula & South Eastern Haematology and Oncology GroupFrankston, Victoria, AustraliaRecruiting
Cabrini HealthMalvern, Victoria, AustraliaWithdrawn
Linear Clinical ResearchPerth, Western Australia, AustraliaRecruiting
The Institute of Oncology, ARENSIA Exploratory Medicine Phase I UnitChisinau, MoldovaRecruiting
National Cancer Centre SingaporeSingapore, SingaporeRecruiting
Tan Tock Seng HospitalSingapore, SingaporeRecruiting
Chungbuk National University HospitalCheongju-si, South KoreaRecruiting

+ 8 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05910827